GLAXF
Price
$17.34
Change
-$0.00 (-0.00%)
Updated
Nov 6 closing price
GSK
Price
$36.52
Change
+$0.62 (+1.73%)
Updated
Nov 7, 03:24 PM (EDT)
90 days until earnings call
Ad is loading...

GLAXF vs GSK

Header iconGLAXF vs GSK Comparison
Open Charts GLAXF vs GSKBanner chart's image
GSK
Price$17.34
Change-$0.00 (-0.00%)
Volume$346
CapitalizationN/A
GSK
Price$36.52
Change+$0.62 (+1.73%)
Volume$2.96K
CapitalizationN/A
View a ticker or compare two or three
GLAXF vs GSK Comparison Chart
Loading...
GSK
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
GLAXF vs. GSK commentary
Nov 07, 2024

To understand the difference between Glaxosmithkline plc (GLAXF) vs. Glaxosmithkline plc - ADR (GSK) it is enough to know the definitions of ADR

ADR - American depositary receipt (ADR) is a certificate issued by a U.S. depositary bank representing a specified number of shares (often 1 share) of a foreign company's stock. ADRs are denominated in U.S. dollars and trade on U.S. stock markets and OTC depending on the ADRs classification.

COMPARISON
Comparison
Nov 07, 2024
Stock price -- (GLAXF: $17.34 vs. GSK: $35.90)
Brand notoriety: GLAXF and GSK are both not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: GLAXF: 20% vs. GSK: 269%
Market capitalization -- GLAXF: $103.73B vs. GSK: $88.13B
GLAXF [@Pharmaceuticals: Major] is valued at $103.73B. GSK’s [@Pharmaceuticals: Major] market capitalization is $88.13B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GLAXF’s FA Score shows that 2 FA rating(s) are green whileGSK’s FA Score has 2 green FA rating(s).

  • GLAXF’s FA Score: 2 green, 3 red.
  • GSK’s FA Score: 2 green, 3 red.
According to our system of comparison, both GLAXF and GSK are a good buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GSK’s TA Score shows that 4 TA indicator(s) are bullish.

  • GSK’s TA Score: 4 bullish, 5 bearish.

Price Growth

GLAXF (@Pharmaceuticals: Major) experienced а -5.35% price change this week, while GSK (@Pharmaceuticals: Major) price change was -3.00% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.40%. For the same industry, the average monthly price growth was -0.67%, and the average quarterly price growth was +9.03%.

Reported Earning Dates

GSK is expected to report earnings on Feb 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-1.40% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GLAXF($104B) has a higher market cap than GSK($88.1B). GLAXF has higher P/E ratio than GSK: GLAXF (17.36) vs GSK (14.01). GSK YTD gains are higher at: -0.444 vs. GLAXF (-5.991). GLAXF has higher annual earnings (EBITDA): 10B vs. GSK (9.08B). GLAXF has more cash in the bank: 14B vs. GSK (4.99B). GSK has less debt than GLAXF: GSK (18B) vs GLAXF (33.3B). GLAXF has higher revenues than GSK: GLAXF (36.5B) vs GSK (30.3B).
GLAXFGSKGLAXF / GSK
Capitalization104B88.1B118%
EBITDA10B9.08B110%
Gain YTD-5.991-0.4441,350%
P/E Ratio17.3614.01124%
Revenue36.5B30.3B120%
Total Cash14B4.99B280%
Total Debt33.3B18B185%
FUNDAMENTALS RATINGS
GLAXF vs GSK: Fundamental Ratings
GLAXF
GSK
OUTLOOK RATING
1..100
5558
VALUATION
overvalued / fair valued / undervalued
1..100
6
Undervalued
7
Undervalued
PROFIT vs RISK RATING
1..100
10081
SMR RATING
1..100
5050
PRICE GROWTH RATING
1..100
6461
P/E GROWTH RATING
1..100
218
SEASONALITY SCORE
1..100
4985

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GLAXF's Valuation (6) in the null industry is in the same range as GSK (7) in the Pharmaceuticals Major industry. This means that GLAXF’s stock grew similarly to GSK’s over the last 12 months.

GSK's Profit vs Risk Rating (81) in the Pharmaceuticals Major industry is in the same range as GLAXF (100) in the null industry. This means that GSK’s stock grew similarly to GLAXF’s over the last 12 months.

GSK's SMR Rating (50) in the Pharmaceuticals Major industry is in the same range as GLAXF (50) in the null industry. This means that GSK’s stock grew similarly to GLAXF’s over the last 12 months.

GSK's Price Growth Rating (61) in the Pharmaceuticals Major industry is in the same range as GLAXF (64) in the null industry. This means that GSK’s stock grew similarly to GLAXF’s over the last 12 months.

GSK's P/E Growth Rating (8) in the Pharmaceuticals Major industry is in the same range as GLAXF (21) in the null industry. This means that GSK’s stock grew similarly to GLAXF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GSK
RSI
ODDS (%)
Bullish Trend 2 days ago
62%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
61%
Momentum
ODDS (%)
Bearish Trend 2 days ago
49%
MACD
ODDS (%)
Bearish Trend 2 days ago
42%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
50%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
50%
Advances
ODDS (%)
Bullish Trend 3 days ago
53%
Declines
ODDS (%)
Bearish Trend 8 days ago
52%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
63%
Aroon
ODDS (%)
Bearish Trend 2 days ago
53%
View a ticker or compare two or three
Ad is loading...
GSK
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
PRAY30.430.69
+2.32%
FIS Christian Stock ETF
SIMS36.300.56
+1.58%
SPDR® S&P Kensho Intelligent Strctr ETF
TDSC25.570.36
+1.41%
Cabana Target Drawdown 10 ETF
PDEC38.670.08
+0.19%
Innovator U.S. Eq Power Buffer ETF - Dec
VYMI71.00-0.95
-1.32%
Vanguard Intl Hi Div Yld Idx ETF

GLAXF and

Correlation & Price change

A.I.dvisor indicates that over the last year, GLAXF has been loosely correlated with GSK. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if GLAXF jumps, then GSK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GLAXF
1D Price
Change %
GLAXF100%
N/A
GSK - GLAXF
37%
Loosely correlated
-3.03%
OPHLY - GLAXF
9%
Poorly correlated
-2.59%
HAWPF - GLAXF
8%
Poorly correlated
N/A
ORINY - GLAXF
6%
Poorly correlated
N/A
GIKLY - GLAXF
5%
Poorly correlated
N/A
More

GSK and

Correlation & Price change

A.I.dvisor indicates that over the last year, GSK has been loosely correlated with NVS. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if GSK jumps, then NVS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GSK
1D Price
Change %
GSK100%
-3.03%
NVS - GSK
37%
Loosely correlated
-2.35%
GLAXF - GSK
36%
Loosely correlated
N/A
JNJ - GSK
35%
Loosely correlated
-0.30%
AZN - GSK
32%
Poorly correlated
-3.67%
SNY - GSK
27%
Poorly correlated
-3.01%
More